Quoin Pharmaceuticals Ltd. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Quoin Pharmaceuticals Ltd. (QNRX) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $532.95 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-14
- Quoin Pharmaceuticals Ltd. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $532.95K, a 65.78% increase year-over-year.
- Quoin Pharmaceuticals Ltd. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $444.52K, a 23.36% increase year-over-year.
- Quoin Pharmaceuticals Ltd. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $182.19K, a 41.82% decline year-over-year.
- Quoin Pharmaceuticals Ltd. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $321.49K, a 2.67% increase year-over-year.
- Quoin Pharmaceuticals Ltd. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $1.15M, a 8.87% decline from fiscal 2024.
- Quoin Pharmaceuticals Ltd. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $1.26M, a 15.01% increase from fiscal 2023.
- Quoin Pharmaceuticals Ltd. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $1.09M, a 43.26% increase from fiscal 2022.
- Quoin Pharmaceuticals Ltd. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $764.01K.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $532.95K 10-Q · filed 2026-08-14 | $977.48K derived: sum of 2 quarters · filed 2026-08-14 | ||
| 2026-03-31 | $444.52K 10-Q · filed 2026-08-14 | |||
| 2025-12-31 | $1.15M 10-K · filed 2026-03-26 | |||
| 2025-09-30 | $182.19K 10-Q · filed 2025-11-06 | $503.67K derived: sum of 2 quarters · filed 2026-08-14 | $864.03K derived: sum of 3 quarters · filed 2026-08-14 | |
| 2025-06-30 | $321.49K 10-Q · filed 2026-08-14 | $681.84K derived: sum of 2 quarters · filed 2026-08-14 | ||
| 2025-03-31 | $360.36K 10-Q · filed 2026-08-14 | |||
| 2024-12-31 | $1.26M 10-K · filed 2026-03-26 | |||
| 2024-09-30 | $313.12K 10-Q · filed 2025-11-06 | $626.24K derived: sum of 2 quarters · filed 2025-11-06 | $932.56K derived: sum of 3 quarters · filed 2025-11-06 | |
| 2024-06-30 | $313.12K 10-Q · filed 2025-11-06 | $619.44K derived: sum of 2 quarters · filed 2025-11-06 | ||
| 2024-03-31 | $306.31K 10-Q · filed 2025-11-06 | |||
| 2023-12-31 | $1.09M 10-K · filed 2025-03-13 | |||
| 2023-09-30 | $268.50K 10-Q · filed 2024-11-08 | $532.88K derived: sum of 2 quarters · filed 2024-11-08 | $794.35K derived: sum of 3 quarters · filed 2024-11-08 | |
| 2023-06-30 | $264.38K 10-Q · filed 2024-11-08 | $525.85K derived: sum of 2 quarters · filed 2024-11-08 | ||
| 2023-03-31 | $261.47K 10-Q · filed 2024-11-08 | |||
| 2022-12-31 | $764.01K 10-K · filed 2024-03-14 | |||
| 2022-09-30 | $267.28K 10-Q · filed 2023-11-09 | $496.72K derived: sum of 2 quarters · filed 2023-11-09 | ||
| 2022-06-30 | $229.44K 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 |